Molecular Templates Inc (MTEM)

$1.33

-0.04

(-3.27%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $1.33
    $1.41
    $1.33
    downward going graph

    0.0%

    Downside

    Day's Volatility :5.67%

    Upside

    5.67%

    downward going graph
  • $1.01
    $9.45
    $1.33
    downward going graph

    24.06%

    Downside

    52 Weeks Volatility :89.31%

    Upside

    85.93%

    downward going graph

Returns

PeriodMolecular Templates IncSector (Health Care)Index (Russel 2000)
3 Months
-19.35%
6.5%
0.0%
6 Months
-63.24%
7.1%
0.0%
1 Year
-84.36%
9.8%
0.0%
3 Years
-98.7%
14.2%
-20.2%

Highlights

Market Capitalization
9.0M
Book Value
$1.09
Earnings Per Share (EPS)
-4.61
PEG Ratio
0.0
Wall Street Target Price
18.0
Profit Margin
-57.92%
Operating Margin TTM
-0.45%
Return On Assets TTM
-26.39%
Return On Equity TTM
-929.14%
Revenue TTM
31.8M
Revenue Per Share TTM
6.48
Quarterly Revenue Growth YOY
-69.69999999999999%
Gross Profit TTM
-46.0M
EBITDA
-16.3M
Diluted Eps TTM
-4.61
Quarterly Earnings Growth YOY
-0.97
EPS Estimate Current Year
-3.43
EPS Estimate Next Year
-3.82
EPS Estimate Current Quarter
-0.78
EPS Estimate Next Quarter
-0.47

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Molecular Templates Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1253.38%

Current $1.33
Target $18.00

Company Financials

FY18Y/Y Change
Revenue
7.3M
↑ 202.45%
Net Income
-30.3M
↑ 30.89%
Net Profit Margin
-415.86%
↑ 545.1%
FY19Y/Y Change
Revenue
19.5M
↑ 167.73%
Net Income
-69.5M
↑ 129.59%
Net Profit Margin
-356.62%
↑ 59.24%
FY20Y/Y Change
Revenue
18.8M
↓ 3.35%
Net Income
104.9M
↓ 250.88%
Net Profit Margin
556.73%
↑ 913.35%
FY21Y/Y Change
Revenue
38.7M
↑ 105.34%
Net Income
-79.3M
↓ 175.6%
Net Profit Margin
-204.96%
↓ 761.69%
FY22Y/Y Change
Revenue
19.8M
↓ 48.95%
Net Income
-92.7M
↑ 16.9%
Net Profit Margin
-469.36%
↓ 264.4%
FY23Y/Y Change
Revenue
57.3M
↑ 190.1%
Net Income
-8.1M
↓ 91.24%
Net Profit Margin
-14.18%
↑ 455.18%
Q4 FY22Q/Q Change
Revenue
2.6M
↓ 38.42%
Net Income
-22.0M
↓ 10.51%
Net Profit Margin
-844.47%
↓ 263.39%
Q1 FY23Q/Q Change
Revenue
33.6M
↑ 1187.9%
Net Income
8.5M
↓ 138.6%
Net Profit Margin
25.31%
↑ 869.78%
Q2 FY23Q/Q Change
Revenue
6.6M
↓ 80.29%
Net Income
-10.9M
↓ 227.71%
Net Profit Margin
-164.0%
↓ 189.31%
Q3 FY23Q/Q Change
Revenue
6.8M
↑ 2.55%
Net Income
4.2M
↓ 138.21%
Net Profit Margin
61.11%
↑ 225.11%
Q4 FY23Q/Q Change
Revenue
7.0M
↑ 3.24%
Net Income
-3.9M
↓ 195.06%
Net Profit Margin
-56.27%
↓ 117.38%
Q1 FY24Q/Q Change
Revenue
11.1M
↑ 58.01%
Net Income
572.0K
↓ 114.49%
Net Profit Margin
5.16%
↑ 61.43%
FY18Y/Y Change
Total Assets
140.2M
↑ 55.06%
Total Liabilities
39.3M
↑ 199.59%
FY19Y/Y Change
Total Assets
174.2M
↑ 24.29%
Total Liabilities
71.2M
↑ 81.33%
FY20Y/Y Change
Total Assets
139.9M
↓ 19.7%
Total Liabilities
80.5M
↑ 13.16%
FY21Y/Y Change
Total Assets
192.4M
↑ 37.52%
Total Liabilities
126.7M
↑ 57.32%
FY22Y/Y Change
Total Assets
97.5M
↓ 49.29%
Total Liabilities
112.7M
↓ 11.07%
FY23Y/Y Change
Total Assets
35.4M
↓ 63.73%
Total Liabilities
31.2M
↓ 72.34%
Q4 FY22Q/Q Change
Total Assets
97.5M
↓ 17.78%
Total Liabilities
112.7M
↓ 1.58%
Q1 FY23Q/Q Change
Total Assets
78.5M
↓ 19.52%
Total Liabilities
80.4M
↓ 28.63%
Q2 FY23Q/Q Change
Total Assets
35.5M
↓ 54.76%
Total Liabilities
44.2M
↓ 45.05%
Q3 FY23Q/Q Change
Total Assets
44.1M
↑ 24.07%
Total Liabilities
37.3M
↓ 15.68%
Q4 FY23Q/Q Change
Total Assets
35.4M
↓ 19.7%
Total Liabilities
31.2M
↓ 16.34%
Q1 FY24Q/Q Change
Total Assets
27.1M
↓ 23.36%
Total Liabilities
21.2M
↓ 31.83%
FY18Y/Y Change
Operating Cash Flow
-4.5M
↓ 68.7%
Investing Cash Flow
-15.9M
↓ 264.13%
Financing Cash Flow
49.2M
↓ 20.28%
FY19Y/Y Change
Operating Cash Flow
-25.2M
↑ 465.38%
Investing Cash Flow
-39.7M
↑ 149.13%
Financing Cash Flow
65.7M
↑ 33.48%
FY20Y/Y Change
Operating Cash Flow
-83.8M
↑ 231.95%
Investing Cash Flow
-34.7M
↓ 12.74%
Financing Cash Flow
58.9M
↓ 10.35%
FY21Y/Y Change
Operating Cash Flow
-30.4M
↓ 63.74%
Investing Cash Flow
-62.4M
↑ 80.13%
Financing Cash Flow
92.6M
↑ 57.22%
FY22Y/Y Change
Operating Cash Flow
-89.0M
↑ 192.97%
Investing Cash Flow
95.3M
↓ 252.65%
Financing Cash Flow
-265.0K
↓ 100.29%
Q4 FY22Q/Q Change
Operating Cash Flow
-18.4M
↓ 24.54%
Investing Cash Flow
28.3M
↑ 44.77%
Financing Cash Flow
-274.0K
↓ 3144.44%
Q1 FY23Q/Q Change
Operating Cash Flow
-19.4M
↑ 5.04%
Investing Cash Flow
26.0M
↓ 8.44%
Financing Cash Flow
-27.5M
↑ 9936.5%
Q2 FY23Q/Q Change
Operating Cash Flow
-9.6M
↓ 50.22%
Investing Cash Flow
3.1M
↓ 87.92%
Financing Cash Flow
-27.5M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Molecular Templates Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Molecular Templates Inc
Molecular Templates Inc
27.31%
-63.24%
-84.36%
-98.7%
-98.66%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Molecular Templates Inc
Molecular Templates Inc
NA
NA
0.0
-3.43
-9.29
-0.26
NA
1.09
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Molecular Templates Inc
Molecular Templates Inc
Buy
$9.0M
-98.66%
NA
-57.92%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Molecular Templates Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 6.62M → 11.08M (in $), with an average increase of 14.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -3.94M → 572.0K (in $), with an average increase of 790.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 146.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 285.2%

Institutional Holdings

  • Bellevue Group AG

    15.64%

  • Bvf Inc

    7.93%

  • SILVERARC CAPITAL MANAGEMENT, LLC

    5.39%

  • Adage Capital Partners Gp LLC

    3.91%

  • Caxton Corp

    2.08%

  • Vanguard Group Inc

    1.92%

Company Information

molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.

Organization
Molecular Templates Inc
Employees
62
CEO
Dr. Eric E. Poma Ph.D.
Industry
Health Technology

Discover More

FAQs